Drug Profile
MIL 77
Alternative Names: MIL-77Latest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Beijing Mabworks Biotech; Chinese Academy of Medical Sciences; Zhejiang Hisun Pharmaceutical
- Developer Beijing Mabworks Biotech; Zhejiang Hisun Pharmaceutical
- Class Anti-infectives; Antibodies; Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ebola virus infections
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for clinical-Phase-Unknown development in Ebola-virus-infections in China (Parenteral)
- 28 Mar 2019 No recent reports of development identified for clinical-Phase-Unknown development in Ebola-virus-infections in United Kingdom (Parenteral)